Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
05/2003
05/08/2003WO2003037877A1 AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037872A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003WO2003037871A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003WO2003037869A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors
05/08/2003WO2003037361A2 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
05/08/2003WO2003037358A1 A pharmaceutical composition having cholagogic and litholytic effect and its preparation method
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037333A1 Pyridine derivatives as nmda-receptor subtype blockers
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037258A2 Methods and compositions for the treatment and diagnosis of pain disorders using 2047
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003US20030087957 Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
05/08/2003US20030087949 For treating neurodegenerative diseases, diseases of circulatory organs, hepatitis, renal diseases, inflammatory skin disorders, radiation disorders, viral diseases, prion diseases, etc.; preservatives
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087903 Mevinolin derivatives
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087255 Peptides which stimulate the immune response and tissue regeneration
05/08/2003US20030087249 93870, a human G-protein coupled receptor and uses therefor
05/08/2003CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2465040A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464888A1 Pyridine derivatives as nmda-receptor subtype blockers
05/08/2003CA2464342A1 Therapeutic isoquinoline compounds
05/08/2003CA2463823A1 Aminobenzamide derivatives as glycogen synthase kinase 3.beta. inhibitors
05/08/2003CA2463822A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
05/08/2003CA2463821A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors
05/08/2003CA2463770A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003CA2462525A1 Type 4 phosphodiesterase inhibitors and uses thereof
05/07/2003EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/07/2003EP1308445A1 5-heteroatom-substituted pyrazoles
05/07/2003EP1308161A1 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases
05/07/2003EP1308158A1 Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/07/2003EP1307559A2 Slit-like protein obtained from a cdna library from hs-5 stromal cell line
05/07/2003EP1307219A2 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
05/07/2003EP1140825B1 Melatonin derivatives and medicine containing same
05/07/2003EP1112251B1 Azetidine derivatives, preparation and medicines containing them
05/07/2003EP1107775B1 Composition containing pyrrolizidine-alkaloid-free petasites
05/07/2003EP1001956B1 2,3-benzodiazepine derivatives
05/07/2003EP0874621B1 [3'-DESOXY-3-OXO-MeBmT]1-[Val]2-CICLOSPORIN-CONTAINING EMULSION PHARMACEUTICAL COMPOSITIONS
05/07/2003EP0806416B1 Huperzine a derivatives, their preparation and their use
05/07/2003CN1416339A IL-8 receptor antagonsts
05/07/2003CN1415344A Specific medicine of natural plants for curing sprain
05/06/2003US6559168 Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/06/2003US6559146 Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins
05/06/2003US6558912 Screening for modulators of apoptosis; obtain cells containing apoptosis polypeptide, incubate with binding protein, expose to modulator, monitor concentration of bound protein in presence of modulator, compare to control
05/06/2003US6558692 Over-coated chewing gum formulations
05/02/2003EP1306093A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305315A2 Polymorphs of zaleplon and methods for the preparation thereof
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1021171B1 Delayed total release gastrointestinal drug delivery system
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035838A2 Stem cells that transform to beating cardiomyocytes
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035042A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002102782A3 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003US20030083505 Benzenedicarboxylic acid derivatives
05/01/2003US20030083466 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
05/01/2003US20030083333 1,4-Disubstituted benzo-fused compounds
05/01/2003US20030083332 N-heterocyclic derivatives as NOS inhibitors
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082153 Stem cells that transform to beating cardiomyocytes
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464088A1 Stem cells that transform to beating cardiomyocytes
05/01/2003CA2463311A1 Androgen receptor modulators and methods of use thereof
04/2003
04/30/2003CN1413645A Composite medicine for treating lumbodynia and method for preparing medicinal cup thereof
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106857C Preparation for treating soft tissue contusion
04/30/2003CN1106851C 三七胶囊 Thirty-seven Capsules
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
1 ... 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 ... 233